Nav: Home

Atlases of immune cells surrounding tumors may guide immunotherapy

May 04, 2017

Two independent studies have begun mapping the connections between and identities of the thousands of immune cells surrounding human tumors. One research group, looking at kidney cancer, found that tumors with different clinical outcomes have unique immune cell profiles. These profiles can also estimate a cancer patient's prognosis. The other group, looking at lung cancer, showed that even early tumors have disturbed immune cell activity. Both papers, appearing May 4 in the journal Cell, could inspire a new wave of precision immunotherapy clinical trials.

"We've found that immune cells start to be dysfunctional very early during tumor formation, but immunotherapy is not typically given until patients relapse and the cancer is advanced," says senior author of the lung cancer study Miriam Merad (@MiriamMerad), of the Mount Sinai School of Medicine in New York. "We want to advocate for starting immunotherapy early, before it is too late."

"Basic researchers are going to be very excited for this toolbox because they can study their immune cell or pathway of interest with higher resolution and compare it across individual tumors or tumor types," says senior author of the kidney cancer study Bernd Bodenmiller (@BodenmillerLab), of the University of Zürich in Switzerland. "For translational researchers, knowing that there are these immune cell differences among patients' tumors presents a tantalizing possibility for personalized immunotherapy."

Immunotherapy is the use of drugs to stimulate immune cells to fight cancer the way they fight foreign invaders. A tumor's ability to grow unchecked is helped by its recruitment of immune cells to keep it hidden from the rest of the immune system. Tumors become so entrenched with our immune cells that they form mini ecosystems, with cell-to-cell relationships not seen in normal tissues. The atlases reveal these ecosystems and the connections between tumor immune cells in unmatched detail, such as which immune cells are present in a specific tumor and the frequency of a given cell type, but also their functional potential.

Both studies generated the atlases by tagging single immune cells around the tumor with 30 to 40 antibodies that could bind to specific markers known to be present on various cells. Using this information, a detector could screen the cells and reveal their identities and whether the cells are functional or defective.

"I think when most people see our data, they will first react with the thought that it's pure chaos," says Bodenmiller, whose group looked at tumor samples from 73 patients with renal cell carcinoma. "But if you look at the distributions of the cell phenotypes for a bit longer, you will see patterns. And then computational analysis reveals that there are relationships between the cell types in the tumor ecosystem that relate to a clinical outcome. We can even put this information into an equation and estimate survival."

Merad's group looked at tumor samples and normal tissue from 28 patients at early or advanced stages of lung adenocarcinoma. Their analysis saw changes in cell type behavior much earlier than anticipated. Stage 1 tumors already showed a rich gathering of suppressive macrophages and T cells, as well as the depletion of NK cells that help activate the immune system. These tumors are typically removed surgically, and while they usually have a good prognosis, 25% of patients relapse.

"In this study we identified many immune suppressive changes that could be targeted to induce an immune attack and an immune memory response against these small tumors, and we are currently testing these questions in animal models," Merad says. "We are very excited about these results because we believe that targeting tumor cells at this small stage has much higher chances to get rid of all tumor cells than if we unleashed an immune attack in larger tumors where risk of tumor cell dissemination is higher."

Both groups described the creation of theirs atlases as significant undertakings and expensive, which means that it won't be something that can be used as a standard of care anytime soon. Bodenmiller predicts the technique will follow the same course as human genome sequencing, in which costs will fall over time. Merad says that generating and sharing these atlases with the cancer research community provides unprecedented knowledge about the cancer immune microenvironment and will help foster knowledge and the rational design of clinical trials.
Cell, Chevrier and Levine et al: "An Immune Atlas of Clear Cell Renal Cell Carcinoma." DOI: 10.1016/j.cell.2017.04.016

The research was funded by the Swiss National Science Foundation, SystemsX, the European Research Council, Roche, EMBO, RACP, CIHR/KCC, NHMRC, the National Institutes of Health, and the Memorial Sloan Kettering Cancer Center.

Cell, Lavin et al.: "Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses."

DOI: 10.1016/j.cell.2017.04.014

The research was heavily funded by the National Institutes of Health. Basic research on immunotherapy is a major focus of the Cancer Moonshot Initiative. Additional support was provided by la Recherche Medicale.

Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Visit To receive Cell Press media alerts, contact

Cell Press

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...